Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 8, 2025American Journal of Clinical Oncology

Real World Radiographic Response Rates and Preoperative Attrition in Patients With Nonsmall Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

CFCole FriedesMIMichelle IocolanoNYNikhil Yegya‐Raman

Discussion

Loading...

Member takes

Overview

Observational analysis found a 58% surgical intervention rate in patients with NSCLC after neoadjuvant chemoimmunotherapy, indicating challenges in patient selection.

Key Points

  • The rate of surgical intervention after neoadjuvant chemoimmunotherapy was 58%, based on patient eligibility for surgery.
  • Toxicity from chemoimmunotherapy and surgery resulted in 42 and 19 adverse events respectively, with some being grade 3 or higher.
  • Analysis of a single-institution database focused on patients with stage II-III nonsmall cell lung cancer.
  • Further validation in external cohorts is needed to improve patient selection for curative surgery.

Cite This Study

Friedes et al. (2025) studied this question.

synapsesocial.com/papers/690e8b6ca5b062d7a4e7355chttps://doi.org/10.1097/coc.0000000000001260
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The efficacy analysis of neoadjuvant chemoimmunotherapy followed by surgery in stage III locally advanced non-small cell lung cancer: a systematic review and meta-analysis2025 · 4 citations
  2. 2Chemoimmunotherapy for Patients with Resectable Non-Small Cell Lung Carcinoma: Real-World Data Analysis from a Surgical Point of View2025
  3. 3Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival2025 · 7 citations
  4. 4Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non‑small cell lung cancer2025
  5. 5Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses2025 · 15 citations